Oren Livnat has given his Buy rating due to a combination of factors including the recent acquisition of Alimera Sciences by ANI Pharmaceuticals, which is expected to be immediately accretive to the ...
On June 24, ANI said it was buying Alimera Sciences for $5.50 per share in cash, in a deal that valued Alimera at $381 million. The offer represented a 75% premium to its closing share price of $3.15 ...
Alimera Sciences has filed a lawsuit in the Delaware Court of Chancery to compel ANI Pharmaceuticals to fulfill its contractual obligation to close the transaction contemplated by the companies ...
Some results have been hidden because they may be inaccessible to you